The objective of this study was to compare, at equal blood pressure (BP) reduction, the effect of two different combinations on metabolic control and albuminuria in type 2 diabetic hypertensive patients with albuminuria. This was a prospective, randomised, double-blind, parallel, controlled trial carried out in 11 Spanish hospitals. A total of 103 type 2 diabetic patients with stable albuminuria and BP not controlled on monotherapy were randomised of which 93 finished the study. After a 4-week single-blind placebo period, patients were randomised to verapamil SR/trandolapril 180/2 mg (VT) or to enalapril/hydroclorothiazide 20/12.5 mg (EH). Treatment duration was 6 months. The main outcome measures were changes in BP, 24-h albuminuria, blood glucose and glycated haemoglobin. Overall BP was significantly reduced from 157.3 ؎ 12.0/98.3 ؎ 6.4 mm Hg to 140.5 ؎ 14.5/86.1 ؎ 8.2 mm Hg (P Ͻ 0.001) and albuminuria significantly decreased from 508.6 ؎ 693.8 mg/24 h to
Introduction
Patients with type 2 diabetes are frequently hypertensive at the time of diagnosis of diabetes. Diabetes is an independent risk factor for coronary heart disease and the risk is doubled when hypertension is also present. In non-insulin dependent diabetes mel-litus (NIDDM) patients, the prevalence of arterial hypertension according to criteria from the JNC-V rises from 71% (normoalbuminuric patients) to 93% (macroalbuminuric patients). 1 Microalbuminuria is a strong predictor of total cardiovascular mortality and morbidity in hypertensive patients with type 2 diabetes. [2] [3] [4] [5] Nephropathy is an important cause of morbidity and mortality in patients with type 2 diabetes, conditioning progression to end-stage renal disease and being the most common single cause of replacement therapy. Risk factors for the frequency, severity and progression of diabetic nephropathy are the degree of hyperglycaemia and associated metabolic disturbances, hypertension as well as duration of diabetes. 6 Chronic hyperglycaemia exacerbates the vascular disease associated with diabetes mellitus and hypertension 7 and accelerates the formation of nonenzymatic advanced glycosilation products. 8 In a population-based study in elderly diabetic patients, glycated haemoglobin (HbA1c) was the most important single risk factor associated with coronary heart disease (CHD) death or all CHD events. 9 The emerging theme that angiotensin-converting enzyme (ACE) inhibitors are superior to most other antihypertensive agents in slowing and preventing the progression of diabetic nephropathy has progressively gained more support. In two metaanalyses, long-term beneficial effects of antihypertensive agents on proteinuria were proportional to blood pressure reductions and ACE inhibitors and possibly non-dihydropyridine (non-DHP) calcium antagonists have additional beneficial effects that are independent of blood pressure reductions. 10, 11 Studies with non-DHP calcium antagonists in diabetic nephropathy demonstrated that beneficial effects in the rate of decline of renal function were comparable with the effects of ACE inhibitors. 12, 13 ACE inhibitors improve glucose use and insulin sensitivity in hypertensive patients with type 2 diabetes mellitus (DM).
14 The adequate control of blood pressure, albuminuria and metabolic parameters can favourably modify the disease course. In the treatment of hypertension in patients with DM, ACE inhibitors probably are drugs of choice for initial monotherapy in patients with albuminuria/ proteinuria. 15 If blood pressure response is inadequate, the use of combinations should be considered. The addition of a non-DHP calcium antagonist or a diuretic would be a prudent course of action. 16 The objective of this study was to evaluate if, in hypertensive patients with well-controlled type 2 diabetes mellitus and albuminuria between 30-3000 mg/day, at equal blood pressure reduction, a non-DHP calcium antagonist would offer a better global protection than low-dose diuretic, both in combination with an ACE-inhibitor.
Materials and methods

Study population
Eleven centres in Spain recruited 120 hypertensive patients with type 2 diabetes who were receiving antihypertensive therapy with one single drug, had a sitting systolic blood pressure (SBP) у140 mm Hg and/or diastolic blood pressure (DBP) у90 mm Hg and stable albuminuria within a non-nephrotic range (30-3000 mg/day). All patients were referred from the outpatients departments of Internal Medicine, Endocrinology or Nephrology. This study population consisted of 79 men (66%) and 41 women (34%) with a mean age (Ϯ standard deviation, s.d.) of 54.9 Ϯ 9.3 years. After a 4-week singleblind placebo run-in period, a total of 103 patients met the inclusion criteria and were randomly assigned to active treatment: 51 to verapamil SR 180 + trandolapril 2 mg (VT) and 52 to enalapril 20 mg + hydrochlorothiazide 12.5 mg (EH). All but 10 patients completed the study. Exclusion criteria were: (1) patients with secondary hypertension; (2) those without pharmacological treatment or receiving a combination of two or more antihypertensive drugs; (3) congestive heart failure (NYHA class III or IV); (4) serum creatinine Ͼ3 mg/dl; (5) known hypersensitivity or intolerance to ACE inhibitors or calcium channel blockers.
Study design
The Institutional Review Boards of all participating centres according to the Spanish law approved the study protocol. The TRAVEND trial had a randomised, double-blind, two-parallel group design. After informed consent was obtained from all participants, patients who had SBP у140 and/or DBP у90 mm Hg, previous diagnostic criteria for diabetes mellitus (fasting plasma glucose у126 mg/dL) 17 and stable albuminuria, confirmed in at least two occasions, in a 30-3000 mg/day range, entered a 4-week single-blind run-in period, during which placebo was given to replace the previous antihypertensive drug. Patients were randomly assigned to receive the fixed combination VT or EH once daily. A random number generator was used to assign the patients 1:1 to each treatment within blocks of irregular size. The list of randomisation numbers was used to label the drug boxes, which were given to the participants sequentially. Both patients and care givers were blinded to treatment, and randomisation codes were not broken until all measurements and statistical analyses had been done. Albuminuria, glycated haemoglobin, serum lipids, routine hematological and blood chemistry analyses (hematological indices, blood glucose, serum sodium and potassium concentrations, liver enzymes levels, uric acid, urea and creatinine concentrations) were done, blind to treatment, at baseline, 12 and 24 weeks of active treatment by a central laboratory (Echevarne Laboratories, Barcelona, Spain). In patients with stable type 2 DM and mild hypertension, the discrepancy in diastolic pressure reduction between casual and 24-h ambulatory monitoring suggests that the method of blood pressure assessment is important when evaluating antihypertensive drug efficacy. 18 Thus, 24-h blood pressure monitoring was recorded at baseline (before starting the active treatment) and after the treatment period. Interview and physical examination assessed side effects, concomitant diseases, and blood pressure at each visit during the treatment. Before entering the study, the metabolic control recommendation was HbA1c Ͻ7%. All patients were counselled to follow a low sodium and carbohydrate diet and investigators were instructed to maintain if possible, the same antidiabetic therapy throughout the study.
Objectives
The main objective was to determine the decrease in 24-h albuminuria in the two groups of treatment. The secondary goal was the degree of metabolic control of the diabetes as assessed by glycosilated haemoglobin (HbA1c) and glucaemic levels.
Outcome measures
Albuminuria was measured by nephelometrie (BNA II I.behring, Mannheim, Germany); HbA1c was measured by liquid chromatography-ionic change (Menarini) and blood glucose by god-pap (Randox).
Casual blood pressure was measured with an appropriate size cuff three times at 2-min intervals after a 10-min rest in the sitting position, using a calibrated mercury sphygmomanometer. Values were estimated as the mean of the three readings. Blood pressures were measured in the same arm at each visit.
Ambulatory blood pressure was monitored using an oscillometric device Spacelab 90207 (Spacelabs Inc, Redmond, WA, USA) on typical work days while the subjects were encouraged to pursue their routine activities. Night time workers were excluded from the study. The cuff size was the adequate size for each arm diameter. The ambulatory blood pressure monitor was mounted on the non-dominant arm between 8.00 and 10.00 am and removed after at least 24 hours. Blood pressure was recorded 3 times per hour from 7.00 am to 11.00 pm (daytime) and every 30 min from 11.00 pm (night time). Recordings were ignored if the monitor indicated an error in more than 25% of assessments or periods longer than 1 h without readings were detected. Subjects were instructed to immobilise their arm during cuff inflation. SBP, DBP, heart rate (HR), mean blood pressure (MBP) and pulse pressure (PP) were evaluated. Hourly means of accepted measures were used for statistical analysis. Safety measurements included assessment of clinical adverse events, laboratory tests as well as electrocardiograms performed at baseline, 4 weeks and at the end of the 24-week treatment period.
Statistical analysis
According to Stornello, in hypertensive, diabetic patients with stable proteinuria enalapril reduced albuminuria by 222 mg/day. 19 A sample size of 80 valuable patients was estimated as necessary to find a difference of 50 mg/day in albuminuria reduction between treatments (␣ ϭ 0.05, ␤ ϭ 0.2 and two-tail analysis). The intention-to-treat sample was defined as randomised patients with at least one postrandomisation efficacy measurement. 'Last observation carried forward' (LOCF) procedure was used to estimate data lost. Per protocol sample comprised patients finalising the 24-week follow-up without major protocol violation. For metabolic control The main objective was analysed on an intention-totreat basis. Repeated measures analysis of variance (ANOVA), with a within subject factor (weeks) and a between subject factor (treatment) was used to analyse the evolution of mean values of SBP, DBP and proteinuria.
Covariance analysis (ANCOVA) adjusted by baseline values was used to compare changes in proteinuria throughout the study. To analyse the blood pressure evolution from ambulatory blood pressure monitoring, a repeated measurements three-way ANOVA with two within subject factor: moment (before and after treatment) and time (hours after drug administration) and a between subject factor (treatment) was used. Diurnal and nocturnal periods were compared with a two-way ANOVA with a within subject factor, moment (before and after treatment) and a between subject factor (treatment). The Student's t-test and two-way ANOVA were used to analyse secondary objectives. ANCOVA adjusted by baseline values was used to estimate blood glucose changes across the study. Frequencies of patients arising criteria for glycaemic control were compared by the McNemar test.
For safety analysis, all randomised patients were included. All statistical tests were two-sided. P values lower than 0.05 were considered as significant. The analysis was developed with the SPSS 9.0 statistical package.
Results
A total of 120 patients entered the run-in phase of the study. After 4 weeks of placebo treatment, 103 qualified for randomisation (51 to VT and 52 to EH). Runin dropout causes were: exclusion criteria, 14 (11, albuminuria out of range; three, creatinine above the admitted limit); severe hypertension, one patient; consent withdrawal, one patient, and adverse event (pneumonia) in one case. The intention-to-treat set was formed by 97 patients (50 on VT and 47 on EH). Ninety-three patients (48 on VT and 45 on EH) completed the 24-week trial. Eighty-eight patients (44 on each arm) were valuable for the secondary objective. The baseline characteristics of the study population are shown in Table 1 .
Casual blood pressure
Overall SBP and DBP were significantly reduced from 157.3 Ϯ 12/98.3 Ϯ 6.4 mm Hg to 140.5 Ϯ 14.5/86.1 Ϯ 8.2 mm Hg (P Ͻ 0.001 in both) mainly in the first 4 weeks (Bonferroni correction, P Ͻ 0.01). The blood pressure reduction was observed in both groups. Overall SBP/DBP reductions were 17/12 mm Hg, being 16/11 for VT and 18/13 for EH; statistical differences among treatments were not found. The blood pressure evolution is shown in Figure 1 .
Ambulatory blood pressure monitoring
Initial and final records of 89 patients were available (45 on VT and 44 on EH). The 24-h SBP and DBP reductions were 6.8 Ϯ 21.0/4.0 Ϯ 12.2 mm Hg on VT group and 8.3 Ϯ 18.6/4.8 Ϯ 10.8 mm Hg on EH group, without differences between treatments. The evolution of the mean hourly SBP/DBP is shown in Figure 2 . The three-way ANOVA demonstrated a significant reduction of 24-h SBP/DBP after treatment (P ϭ 0.001 in both). A significant interaction time × moment demonstrated a greater effect of drugs during the diurnal than during the nocturnal period (P ϭ 0.001 for SBP and DBP P ϭ 0.003 for DBP). The analysis of the mean values of SBP/DBP showed a statistical reduction during the diurnal period (P Ͻ 0.0005 in both), but not during the night time (P ϭ 0.058 for SBP and P ϭ 0.073 for DBP 
Albuminuria
Globally, albuminuria was reduced from 508.6 Ϯ 693.8 mg/24 h to 253.4 Ϯ 517.2 mg/24 h (ANOVA, P Ͻ 0.001). At the same blood pressure reduction, both treatments showed similar antialbuminuric effect. In the intention-to-treat data set, the crude reductions in albuminuria were 261 Ϯ 648.4 for VT and 248 Ϯ 441.7 mg/day for EH. The estimated mean albuminuria reduction, adjusted by baseline values, were 210.4 (95% Cl: 94.8 to 326.1) mg/day for VT and 302.9 (95% Cl: 183.6 to 422.2) mg/day for EH, without statistical differences between treatments (ANCOVA, P ϭ 0.274). The albuminuria segmented analysis, in function of baseline values (Ͻ300 mg/day or у300 mg/day), showed no signifi- cant differences between treatments either in the group with an initial microalbuminuria or in the group with overt proteinuria ( Table 2 ). The evolution of mean values of proteinuria is shown in Figure 3 . The results obtained in the intention-totreat set were confirmed in the per protocol sample.
Metabolic control
Concerning HbA1c (Figure 4 ), this parameter globally changed from 5.93 Ϯ 1.34% baseline to 6.17 Ϯ 1.58 (ANOVA, P ϭ 0.018). Mean values were not modified on VT: baseline: 5.91 Ϯ 1.43%, end of treatment: 5.94 Ϯ 1.62%, but increased on EH: baseline, 5.96 Ϯ 1.25%; final, 6.41 Ϯ 1.51%, showing a statistical difference between treatments (ANOVA interaction factor, P ϭ 0.040). Figure 1 ). Figure 4 HbA1c changes, baseline and at 24 treatment weeks. HbA1c was not modify by VT but increased on EH (ANOVA P = 0.040). (HbA1c, glycosilated haemoglobin; VT and EH meaning as in Figure 1 ).
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Mean blood glucose changed from 143 Ϯ 55 mg/dL to 119 Ϯ 53 mg/dL in the VT group and from 133 Ϯ 34 mg/dL to 132 Ϯ 42 mg/dL in the EH group (ANOVA, P ϭ 0.018). The crude blood glucose changes were 23 Ϯ 69 for VT (16.8% reduction) and 1 Ϯ 32 mg/dL for EH (0.8% reduction). ANCOVA estimated mean glucose reductions adjusted by baseline values were 20 (95% CL: 7 to 34) mg/dL for VT and 4 (95% Cl: −9 to 18) mg/dL for EH.
The percentage of patients with glucaemic control (blood glucose Ͻ126 mg/dL) increased from 50% on week 0 to 72.7% on week 24 on VT, improving in 29.5% and worsening in 6.8% of patients (McNemar Journal of Human Hypertension test, P ϭ 0.021) and did not change on EH: 47.7% on week 0 vs 50% on week 24, improving in 13.6% of patients and worsening in 11.4% (McNemar test, P ϭ 1.000).
Renal function and other biochemical parameters
The evolution of mean values of serum creatinine, creatinine clearance, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, uric acid and potassium are presented in Table 2 . No differences among treatments were found in all these parameters.
Safety analysis
All the 103 randomised patients were considered for the safety analysis. The tolerability profile was similar between treatments. Throughout the active period of the study, 59 adverse events were reported in 31 patients: 30 adverse events in 15 patients (29.4%) on VT; 29 adverse events in 16 patients (30.8%) on EH. Symptoms were of mild/moderate intensity in most of cases. Two patients, one in each arm, interrupted the study because of adverse events (oedema in both cases). Eight other patients did not finish the study because of several reasons: protocol violation, five patients, and poor BP control, three patients.
Discussion
The main findings of this study are that in type 2 diabetic patients with albuminuria and blood pressure not controlled on monotherapy, the antihypertensive and antialbuminuric efficacy of the fixed combination trandolapril 2 mg plus verapamil SR 180 mg is similar to enalapril 20 mg plus HCTZ 12.5 mg. However, the trandolapril+verapamil combination seems to allow a better metabolic control than enalapril+HCTZ (0.45% difference in HbA1c levels, P ϭ 0.04), factor to be considered in the longterm treatment of diabetic nephropathy. Both combination therapies result in similar safety and tolerability. SBP and DBP were reduced throughout the study, without differences between treatments, both in casual and ABPM methods.
Intensive therapy and improved glycaemic control delays the onset and slows the progression of retinopathy, nephropathy and neuropathy in IDDM and type 2 diabetes patients, decreasing the risk of microvascular complications. 20, 21 In the UKPDS, 22 a difference of 0.9% in HbA1c was associated with a risk reduction of 36% for all-cause mortality (9-55, P ϭ 0.011) and with a 42% for diabetes-related death (9-63, P ϭ 0.017). In a very recent cohort study, in 4662 men followed for 2 to 4 years, an increase of 1% in HbA1c was associated with 28% (P Ͻ 0.002) increase in risk of death independent of age, blood pressure, serum cholesterol, body mass index and cigarette smoking habit. Glycated haemoglobin concentration seems to explain most of the excess mortality risk of diabetes in men. 23 The HbA1c level is a significant predictor of increased mortality from all causes as well as for cardiovascular disease. [24] [25] [26] Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria slows progression to nephropathy, and progression of retinopathy and autonomic neuropathy. 27 There is increasing concern regarding the metabolic effects of antihypertensive drug therapy and their impact on cardiovascular risk reduction resulting from the treatment of hypertension. 28 Hypertensive subjects taking beta-blockers or diuretics, or both, have an increased risk of diabetes compared to hypertensive subjects not taking those agents. 29 Diuretics, at least in high doses, have been associated with glucose intolerance. 30 Thiazideinduced glucose intolerance is related to development of insulin resistance. In contrast, calcium channels blockers do not appear to alter insulin sensitivity. 31 Adverse effect of diuretics on glycaemic control is reflected on a rise in serum glucose and glycated haemoglobin levels. 32 In a small (10 patients), non-randomised study in hypertensive NIDDM patients, after 8 weeks of enalapril, 12.5 mg/day of hydrochlorotiazide was added in five patients whose DBP was Ͼ90 mm Hg and treatment was continued in the two groups for a second period of 8 weeks. No significant difference was observed in any of the metabolic characteristics between both groups, probably due, in our opinion, to the small sample size. 33 Similarly, in a double-blind, randomised study in 114 hypertensive type 2 diabetic patients treated for 20 weeks with either bendroflumethiazide or enalapril, the HbA1c was increased similarly by both treatments (0.4% for the thiazide and 0.2% for the enalapril). The thiazide, however, was also associated with a significant rise in fasting plasma glucose. 34 A recent review of clinical trials indicates that most hypertensive patients with diabetes require more than one agent to achieve blood pressure control. 35 The choice of the second antihypertensive agent could influence the risk of these patients. The data in this paper support the recommendations offered by this recent consensus, in which it is suggested that, after the initial ACE inhibition therapy, adding a non-DHP calcium channel blocker or low-dose thiazide diuretic offers an augmented benefit for further blood pressure reduction. The initial level of HbA1c in our patients (5.93%) is to be noticed; although starting from an excellent metabolic situation, the different effect on metabolic control between the combinations compared in this trial suggests for the first time that when blood pressure response to the initial ACE inhibitor is inadequate, adding a non-DHP calcium antagonist can be preferable to low-dose diuretic. It is necessary to take into account that, as this study started before the recent recommendations of a goal blood pressure of Ͻ130/85 mm Hg 36,37 in diabetic patients, probably the best possible reduction in albuminuria was not obtained. Verapamil improves the tolerance for oral glucose in patients with type 2 diabetes 38 and appears to have no additive hypoglycaemic effect to sulfonylurea. Studies in rats suggest that verapamil inhibits the effect of glucagon stimulation at the hepatocyte level. 39 Absolute or relative hyperglyconaemia often prevails in patients with type 2 diabetes, 40 so it is conceivable that verapamil blocks the effect of such glucagon predominance and thereby reduces the glucose response to glucose ingestion in type 2 diabetic patients.
The combination of trandolapril with verapamil reduces albuminuria to a greater extent than either agent alone 41, 42 or more compared with a betablocker and a low-dose diuretic combination, although blood pressure lowering was similar. 43 In a multicentre, randomised, double-blind study, in patients with hypertension and type 2 diabetes on stable therapy, after 20 weeks of treatment, those on the combination verapamil SR plus trandolapril had lower HbA1c values compared to patients treated with atenolol plus chlorthalidone (7.8 vs 8.6%, P ϭ 0.001), demonstrating a significantly more favourable profile on glycaemic control. 44 The data of all these studies and the present results make the combination verapamil plus trandolapril very attractive in hypertensive diabetic patients not controlled with monotherapy.
